OSI Pharmaceuticals to Announce Fourth Quarter and Year-End 2008 Financial Results on February 19, 2009
February 09 2009 - 9:00AM
Business Wire
OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that
its fourth quarter and year-end 2008 financial results will be
released on February 19, 2009, after the markets close. Following
the announcement, OSI�s management will host a live conference call
and webcast at 5:00 p.m. Eastern Time to review the Company�s
financial results, product portfolio and business developments.
To access the live webcast or the fourteen-day archive via the
Internet, log on to www.osip.com. Please connect to the Company's
website at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be needed to
access the webcast. Alternatively, please call 1-877-852-6578
(U.S.) or 1-719-325-4826 (international) to listen to the call. The
conference ID number for the live call is 2105141. Telephone replay
is available approximately two hours after the call through March
5, 2009. To access the replay, please call 1-888-203-1112 (U.S.) or
1-719-457-0820 (international). The conference ID number is
2105141.
About OSI
Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and
changing lives" by discovering, developing and commercializing
high-quality and novel pharmaceutical products designed to extend
life and/or improve the quality of life for patients with cancer
and diabetes/obesity. The Company�s oncology programs are focused
on developing molecular targeted therapies designed to change the
paradigm of cancer care. OSI�s diabetes/obesity efforts are
committed to the generation of novel, targeted therapies for the
treatment of type 2 diabetes and obesity. OSI's flagship product,
Tarceva� (erlotinib), is the first drug discovered and developed by
OSI to obtain FDA approval and the only EGFR inhibitor to have
demonstrated the ability to improve survival in both non-small cell
lung cancer and pancreatic cancer patients in certain settings. OSI
markets Tarceva through partnerships with Genentech, Inc. in the
United States and with Roche throughout the rest of the world. For
additional information about OSI, please visit http://www.osip.com.
This news release contains forward-looking statements. These
statements are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ
materially from the statements made. Factors that might cause such
a difference include, among others, the completion of clinical
trials, the FDA and other foreign review processes and other
governmental regulation, OSI's and its collaborators' abilities to
successfully develop and commercialize drug candidates, competition
from other pharmaceutical companies, the ability to effectively
market products, and other factors described in OSI
Pharmaceuticals' filings with the Securities and Exchange
Commission.
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Osi Pharmaceuticals Inc. (MM) (NASDAQ): 0 recent articles
More OSI Pharmaceuticals, Inc. News Articles